Our vision is to drive drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen, and personalize medicines.
We approach scientific research cautiously and with a critical eye. We strive to be accurate and precise in our scientific communications. We reward our team for standing up for what they believe to be right, challenging the status quo, and uncovering new ways of driving innovation even if it means going against the grain and adjusting a conventional way of of approaching a problem.
We commit ourselves to constantly developing new technologies and improving existing ones. We believe that innovation is the foundation of scientific discovery, and we pride ourselves on the cutting-edge technologies we continuously bring to our clients.
We are transforming how scientists interact with technologies. Our intuitive user interface is designed with users in mind. We are dedicated to providing users an enjoyable experience while helping them to make sound research decisions.
We recognize that we cannot do it all ourselves. We are able to produce highly enabling technologies by working closely with other innovative organizations. Creating synergy is what we pursue in both our technology and within our collaborations.
Over 50 years of combined experience and expertise in bioinformatics, pharmaceutical research, and business strategy.
President and CEO
Naheed received his MBA from the University of Toronto, Rotman School of Management. Prior to joining Cyclica, Naheed worked as an Associate Director at Bank of Montreal in Calgary where he was integral in multiple cross-border sponsor coverage deals.
An avid lover of travel, sports, jazz. Naheed waits impatiently for the collaboration between his two favourite artists: Miles Davis and Drake.
Dr. Andreas Windemuth, Ph.D.
Chief Science Officer
Prior to joining Cyclica, Andreas served as Chief Information Officer at Firefly BioWorks, a biotechnology company started out of MIT, where he created all computational aspects of the company’s multiplexed assay technology. Andreas is a fellow of the Boehringer Ingelheim Fonds (Stuttgart, Germany), and has done post-doctoral research on biomolecular modeling at the National Center for Supercomputing Applications and Columbia University. Andreas has coauthored over 60 peer-reviewed publications and is named inventor on 7 issued US patents.
Andreas will happily try any beer, so long as it's a German Weiss.
Dr. Andy Hope, Ph.D.
VP of Sales and Business Development
After obtaining his PhD in Chemistry from University College London (UCL), Andy spent his first ten years focused upon two pioneers in the field of Computer Aided Molecular Design: Chemical Design and Biosym Technologies (both companies eventually became part of Accelrys, now known as Biovia). After a further seven years at Aspen Technology he then assumed increasing levels of leadership responsibility at companies including Director of Business Development at GeneFormatics, Solutions Executive at IBM Healthcare and Life Sciences, Director of Business Development at GeneGo (Systems Biology), Director of Discovery and Translational Science at Thomson Reuters, and most recently Senior Director, Business Development and Strategic Alliances at Bio-ReferenceLabs/GeneDx.
Andy is an avid fan of "world" football who also enjoyed playing, refereeing and coaching. He currently manages his fantasy premier league team!
Dr. Shane Climie, Ph.D.
VP of Corporate Development
Prior to joining Cyclica, Shane has more than 25 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and technology development, and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning. Shane has been a Principal at Popper and Company for 11 years where he has provided interim executive management services to early-stage biotechnology companies in the areas of diagnostics and drug discovery / drug development as well as support in the areas of business management, marketing strategy and technology or opportunity assessment. Prior to joining Popper and Company, Shane held several positions at Protana (formerly MDS Proteomics) including Senior Vice President of Science Strategy and Business Development, Senior Vice President of Research Collaborations, and Vice President of Proteomics and Business Development. Dr. Climie was also co-founder, Vice President and Chief Technology Officer of MDS Ocata and was a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. Prior to that, Dr. Climie held several managerial positions at Allelix Biopharmaceuticals, Inc. including Principal Scientist. Dr. Climie completed postdoctoral work at the University of California at San Francisco and received a Ph.D. in Medical Biophysics from the University of Toronto.
Shane is an avid and talented wildlife photographer.
Chief of Staff
Prior to joining Cyclica, Gary spent considerable time undertaking independent management consulting projects mainly for start-up clients, as well as developing early stage investments in new ideas. His experience includes strategic planning and execution in IT, marketing and business development, and operations. Prior to this, Gary worked in wireless telecom as well as with consumer prepaid products in various marketing, operations, and planning roles. Gary’s well developed sense of planning, derived from years of cross-functional project success, and a just-do-it mentality, has been honed to help emerging companies find their footing and execute well. Gary is a graduate of the University of Toronto Rotman School of Management where he obtained an MBA, as well as Carleton University’s School of Computer Science where he obtained a Bachelor’s Degree in Computer Science.
Gary is one with the force, and the force is with him.
Dr. Mostafa Analoui, Ph.D.
Chairman of the Board
Prior to joining Cyclica, Dr. Analoui served as Head of Healthcare and Life Science at The Livingston Securities. He also served as the Senior Director and the Groton/New London Site Head for Global Clinical Technology of Pfizer Inc. Global Research and Development from 2001 to February 2008, where he led the platform technology mission for the clinical development and commercial division in areas including computational medicine. He is also an Adjunct Professor Biomedical Engineering and Entrepreneurship at University of Connecticut, Brown University and Northeastern University. He has been a member of the Board of Directors of Calando Pharmaceuticals, Inc. (known as Insert Therapeutics, Inc.), BPT Pharma, BEACON (Biomedical Engineering Alliance and CONsortium), and NanoBusiness Alliance. Providing industry leadership in the biomedical and technology fields, Dr. Analoui is actively involved in investment, management, and scientific/business development of nanotechnology, drug discovery/development, diagnostic imaging, and global strategies. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports. He holds two patents in quantitative and clinical imaging. He has received his Ph.D. from Purdue University, followed by Post-Doctoral Fellowship at IBM TJ Watson Research Center in NY.
Franklyn D. Prendergast, M.D., Ph.D.
Michael T.R. List, J.D.
In the early 2000s, Michael co-founded and served as Chief Operating Officer of a multi-national computer hardware distributor. In the late 2000s, he was a co-founder and Chief Operating Officer of a private Canadian currency exchange brokerage which was sold two and a half years after its inception. Michael is also currently a director and General Counsel of Smart Energy Instruments, an international fabless semi-conductor company. Michael has a B.A.H. from Queen’s University and an LL.B. from Queen’s University. Michael was called to the bar of the Law Society of Upper Canada in 2000.
Scientific Advisory Board
Dr. Shoshana Wodak, Ph.D.
Dr. Rick Panicucci, Ph.D.
Dr. Panicucci is currently the Vice President of Pharmaceutical Development at WuXi AppTec responsible for providing scientific leadership in the areas of Developability, Formulation Development and GMP Manufacturing. Prior to WuXi he held the position of Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015, where he led the development and implementation of innovative dosage form designs and continuous manufacturing paradigms. He worked closely with Novartis BD&L and Venture Fund on many external deals such as Proteus Digital Health, MicroChips, 7th Sense Bio, West Pharma, Unilife, MIT and University of Toronto to mention a few. Dr. Panicucci currently holds the position of Adjunct Professor at Massachusetts College of Pharmacy. His education includes two post-doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute. Dr. Panicucci received his Ph.D. in Physical Organic Chemistry from the University of Toronto.
John F. Conway
Business and Strategic Advisors
Nathaniel Lipkus, J.D.
Nathaniel Lipkus’ practice at Osler LLP involves assisting clients in civil and intellectual property, litigation and policy matters, with an emphasis on pharmaceutical issues including drug intellectual property, pricing and reimbursement, biologics, and protection against counterfeit. Nathaniel has represented software and energy companies, brand name and generic drug manufacturers, and chemical suppliers in various aspects of patent proceedings in Canada. He has represented clients before the Federal Court of Canada and Federal Court of Appeal and Ontario Superior Court and Divisional Court. He has also advocated on behalf of clients before the Ontario Minister of Health and Competition Bureau in Canada, and the Food & Drug Administration, Federal Trade Commission and U.S. Congress in the United States. Nathaniel graduated in 2006 receiving the Gold Medal in the JD/MBA program at the University of Toronto’s Faculty of Law and the Rotman School of Management.
Dr. Jeremy Grushcow, Ph.D., J.D.
Dr. Jeremy Grushcow is the Chief Business Officer of Sequence Bio, a privately-held data driven drug discovery company based in St. John’s, NL. He has fifteen years’ experience with public and private companies, and venture capital and private equity firms, in the acquisition, financing, development, operation, licensing and sale of pharmaceutical and life sciences businesses. Prior to Sequence, Dr. Grushcow was the EVP, Strategic Development at Antibe Therapeutics, where he was a member of senior management team and was responsible for business development, legal functions, and risk management. Dr. Grushcow holds a B.Sc. (Human Biology) from the University of Toronto, a Ph.D. (Molecular Genetics & Cell Biology) from the University of Chicago, and a J.D. with honors from the University of Chicago Law School, where he was awarded the John M. Olin Prize, given to the outstanding student in Law and Economics.